Exploring the latest emerging drugs for the treatment of sickle cell disease
- 2 October 2025
- journal article
- review article
- Published by Taylor & Francis in Expert Opinion on Emerging Drugs
- Vol. 30 (4) , 263-281
Abstract
1. Sickle cell disease (SCD) is an inherited autosomal recessive hemoglobinopathy marked by structurally abnormal hemoglobin S (HbS). It is thought to affect 3 to 6 million people in the world, mos...Keywords
This publication has 157 references indexed in Scilit:
- Primary myelofibrosis in untreated sickle cell disease: Are adult patients at higher risk for developing hematological myeloid neoplasms?American Journal of Hematology, 2021
- A pilot study of the effect of atorvastatin on endothelial function and albuminuria in sickle cell diseaseAmerican Journal of Hematology, 2019
- Hyperfiltration during early childhood precedes albuminuria in pediatric sickle cell nephropathyAmerican Journal of Hematology, 2018
- Losartan for the nephropathy of sickle cell anemia: A phase‐2, multicenter trialAmerican Journal of Hematology, 2017
- Inactivation of HDAC1 or HDAC2 induces gamma globin expression without altering cell cycle or proliferationAmerican Journal of Hematology, 2015
- A double‐blind, placebo‐controlled phase II study of the efficacy and safety of 2,2‐dimethylbutyrate (HQK‐1001), an oral fetal globin inducer, in sickle cell diseaseAmerican Journal of Hematology, 2014
- A dose‐escalation phase IIa study of 2,2‐dimethylbutyrate (HQK‐1001), an oral fetal globin inducer, in sickle cell diseaseAmerican Journal of Hematology, 2013
- The cost of health care for patients with sickle cell diseaseAmerican Journal of Hematology, 2009
- Clinical trials in sickle cell disease: Adopting the combination chemotherapy paradigmAmerican Journal of Hematology, 2007
- Effect of Hydroxyurea on Mortality and Morbidity in Adult Sickle Cell AnemiaJAMA, 2003